Monday, November 14

1:00 - 8:00 p.m. Registration
Bridge

1:30 - 3:30 p.m. Educational Session 1: Drug Discovery
Ballroom
Chairperson: Christopher J. Michejda, National Cancer Institute-FCRDC, Frederick, MD

- Preclinical Development of Halichondrin B and Its Derivative Eisai E7389*
  David J. Newman, National Cancer Institute-FCRDC, Frederick, MD
- Rescue of Protein Misfolding: A Novel Strategy in the Search for Anticancer Drugs*
  W. Christian Wigley, Reata Pharmaceuticals, Inc., Dallas, TX
- The Use of Medium- and High-Throughput Protein Crystallography in the Discovery of Cancer Therapeutics*
  Dirkson E. Bussiere, Chiron Corporation, Emeryville, CA

3:45 - 5:30 p.m. Educational Session 2: Drug Development
Ballroom
Chairperson: John T. Hunt, Bristol-Myers Squibb Co., Princeton, NJ

- Polymeric Materials in Targeted and Sustained Drug Delivery for Cancer*
  Justin Hanes, Johns Hopkins University, Baltimore, MD
- Discovery of Dasatinib (BMS-354825), A Dual Src/Abl Kinase Inhibitor with Potent Anti-Tumor Activity in Preclinical Assays*
  Louis J. Lombardo, Bristol-Myers Squibb Co., Princeton, NJ
- Discovery and Development of Synthetic Halichondrin B Analog E7389*
  Bruce A. Littlefield, Eisai Research Institute, Andover, MA

5:30 - 6:00 p.m. Special Address
Ballroom
Science with a Purpose
Andrew C. von Eschenbach, Acting Commissioner, Food and Drug Administration, Bethesda, MD

Tuesday, November 15

7:00 - 8:00 a.m. Continental Breakfast
Grand Hall

8:00 - 8:05 a.m. Opening Remarks
Ballroom
Lynn M. Matrisian, Past President, AACR
Anna D. Barker, Deputy Director for Strategic Scientific Initiatives, NCI
Alexander M. M. Eggermont, President, EORTC

8:05 - 10:05 a.m. Keynote Talks
Ballroom

- TGF-β: From Oncogene to Tumor Suppressor to Therapeutic Target in Human Neoplasia
  Carlos L. Arteaga, Vanderbilt University, Nashville, TN
- Discovery and Development of Avastin
  Napoleone Ferrara, Genentech, Inc., South San Francisco, CA

10:05 - 10:30 a.m. Coffee Break
Ballroom Foyer

10:30 a.m. - 12:30 p.m. Plenary Session 1: New Targets in Angiogenesis
Ballroom
Chairpersons: Lee M. Ellis, UT M. D. Anderson Cancer Center, Houston, TX, and Robert S. Kerbel, Sunnybrook and Women's College Health Sciences Center, Toronto, ON, Canada

Overview*
Lee M. Ellis

- Semaphorins and Neuropilins Are Regulators of Tumor Angiogenesis*
  Michael Klagesbrun, Children’s Hospital, Boston, MA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
Notch Signaling in Angiogenesis and Melanoma Progression*
Meenhard Herlyn, The Wistar Institute, Philadelphia, PA

Suppression of Angiogenesis and Tumor Growth by Selective Inhibition of Angiopoietin-2*
Jonathan D. Oliner, Amgen, Thousand Oaks, CA

Integrin alpha-4 beta-1 as a Novel Tumor Molecular Target*
Judith A. Varner, Moores UCSD Cancer Center, La Jolla, CA

12:30 - 2:30 p.m. Poster Session A/Exhibits
Hall C

2:30 - 4:30 p.m. Plenary Session 2: Identifying Molecular Targets for Cancer Prevention
Ballroom

Chairpersons: Eva Szabo, National Cancer Institute, Bethesda, MD, and Andrew J. Dannenberg, New York Presbyterian Hospital, New York, NY

Identifying Molecular Targets for Cancer Prevention: Overview*
Eva Szabo

Aromatase and ER as Targets for Prevention in Breast Cancer*
Mitchell Dowsett, Royal Marsden Hospital, London, England

Interactions of Triterpenoids and Rexinoids in Cancer Prevention and Treatment
Michael B. Sporn, Dartmouth Medical School, Hanover, NH

Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Andrew J. Dannenberg

4:30 - 5:30 p.m. Proffered Paper Session 1
Ballroom

Molecular Analysis of EGFR Gene Copy Number, EGFR Expression and Akt Activation Status in Advanced Non-Small-Cell Lung Cancer (aNSCLC) Treated with Gefitinib or Placebo (ISEL trial)
Fred Hirsch, University of Colorado Cancer Center, Aurora, CO

Epidermal Growth Factor Receptor (EGFR), K-Ras and B-Raf Mutation Status and Clinical Outcome to Gefitinib (IRESSA) in a Phase III Placebo-controlled Study (ISEL) in Advanced Non-small-cell Lung Cancer (aNSCLC)
Brian Holloway, AstraZeneca Pharmaceuticals, Macclesfield, England

A Phase I Single Dose Escalation Study of the Polo-like Kinase 1 Inhibitor BI 2536 in Patients with Advanced Solid Tumors
Gerd M. Munzert, Boehringer Ingelheim Pharma GmbH and Company KG, Biberach, Germany

T670X Kit Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense
Sabrina Pricl, University of Trieste, Trieste, Italy

5:30 - 7:30 p.m. Poster Session A (continued)/Exhibits
Hall C

Wednesday, November 16

7:00 - 8:00 a.m. Continental Breakfast
Grand Hall

8:00 - 10:00 a.m. Plenary Session 3: Targeted Molecular Imaging
Ballroom

Chairperson: Daniel C. Sullivan, National Cancer Institute, Bethesda, MD

Overview
Sanjiv Sam Gambhir, Stanford University, Stanford, CA

The Use of Imaging to Advance Immune Cell-Mediated Delivery of Therapeutics
Christopher H. Contag, Stanford University, Stanford, CA

Imaging and Targeted Therapy: Using PET in Clinical Trials and Clinical Practice*
David A. Mankoff, University of Washington, Seattle, WA

Functional Molecular Imaging to Predict and Monitor Response to Targeted Therapy*
Robert J. Gillies, Arizona Cancer Center, Tucson, AZ

10:00 - 10:30 a.m. Coffee Break
Ballroom Foyer

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
10:30 a.m. - 12:30 p.m.  Plenary Session 4: Optimizing Therapies for Inhibiting Kinase Receptors
Ballroom
Chairpersons: Dennis J. Slamon, UCLA School of Medicine, Los Angeles, CA, and José Baselga, Vall d’Hebron University Hospital, Barcelona, Spain

Update on HER2 Directed Therapy
Dennis J. Slamon

Update on the Epidermal Growth Factor Receptor Targeting
José Baselga

Linking Somatic Genetic Alterations in Cancer to Therapeutics
William R. Sellers, Dana-Farber Cancer Institute, Boston, MA

Disrupting IGF Receptor Signaling as a Cancer Therapy
Douglas Yee, University of Minnesota, Minneapolis, MN

12:30 - 2:30 p.m.  Poster Session B/Exhibits
Hall C

2:30 - 4:30 p.m.  Concurrent Sessions

Concurrent Session 1: Phase II Trial Design
Room 201
Chairpersons: Mark J. Ratain, University of Chicago, Chicago, IL, and Robert Temple, Food and Drug Administration, Rockville, MD

Oncology's Trials: Do Phase II Trials Adequately Predict Success in Phase III?*
Robert H. Glassman, Cornell/Merrill Lynch, New York, NY

Title to be announced
Robert Temple, Food and Drug Administration, Rockville, MD

Phase II Trial Design in Oncology Drug Development*
Susan D. Desmond-Hellmann, Genentech, Inc., South San Francisco, CA

Randomized Discontinuation Trials*
Mark J. Ratain

Concurrent Session 2: The Proteome and Drug Development
Room 204
Chairpersons: Stephen Barnes, University of Alabama, Birmingham, AL, and David C. Muddiman, Mayo Clinic College of Medicine, Rochester, MN

Rethinking Agonism and Antagonism of Drugs through the Eyes of Proteomics*
Stephen Barnes

Ovarian Cancer Biomarker Discovery: A Tale of Technologies*
David C. Muddiman

Disease-Relevant Protein Drug Targets from Proteomics of Anti-oxidant Actions in Normal Tissues*
Helen Kim, University of Alabama, Birmingham, AL

Attacking Accessible Tumor Targets via Proteomic Mapping and Imaging of Vascular Endothelium and Its Caveolae In Vivo
Jan E. Schnitzer, Sidney Kimmel Cancer Center, San Diego, CA

Concurrent Session 3: Nanotechnology and Drug Development
Marriott Hotel Grand Ballroom ABF, 5th Floor
Chairperson: Esther H. Chang, Georgetown University, Washington, DC

Tumor-Targeting Nanodelivery Systems: Expanding the Potential for Cancer Therapy and Diagnosis*
Esther H. Chang

Targeted Nanoparticle Beacons for Quantification of Molecular Epitopes and Drug Delivery*
Samuel A. Wickline, Washington University, St. Louis, MO

Nanodevices for Noninvasive Detection, Diagnosis and Treatment of Cancer
James R. Baker, Jr., University of Michigan, Ann Arbor, MI

Nanomechanical Methods for Molecular Analysis of Cancer
Mauro Ferrari, Ohio State University, Columbus, OH

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
Concurrent Session 4: Nuclear Enzymes as Mediators and Attenuators of Drug Action
Marriott Grand Ballroom CDE, 5th Floor

Chairpersons: Annette K. Larsen, Institut Gustave-Roussy, Villejuif, France, and Giovanni Melillo, National Cancer Institute, Frederick, MD

Topoisomerase II alpha Directly Influences the Cellular Resistance to Microtubule-Interacting Agents*
Annette K. Larsen

Clinical Potential of DNA Repair Inhibitors*
Roger J. Griffin, University of Newcastle upon Tyne, Newcastle upon Tyne, England

Targeting the Multiple Functions of Topoisomerase I*
Christian Bailly, Pierre Fabre Research Institute, Toulouse, France

Targeting Topoisomerases to Inhibit Hypoxia Inducible Factor 1 (HIF-1): Mechanism and Clinical Implications*
Giovanni Melillo

4:30 - 5:30 p.m. Proffered Paper Session 2
Ballroom

Discovery of Potential Biomarkers Modulated by Treatment with Anti-angiogenesis Agent BMS-582664
Mark D. Ayers, Bristol-Myers Squibb Company, Pennington, NJ

Preliminary Studies Regarding the Application of Localized Fluorine Magnetic Resonance Spectroscopy (19F-MRS) at Ultra High Magnetic Field (7 Tesla), for Non-invasive, In Vivo Monitoring of Gemcitabine and Its Active Anabolic Byproduct Tri-phosphate (dFdCTP) in Human Pancreatic Cancer Cells
Leonard Liebes, New York University Cancer Institute, New York, NY

Final Clinical, Pharmacokinetic and Pharmacodynamic Results of the Phase I Study of the Novel Poly (ADP-ribose) polymerase (PARP) Inhibitor, AGO14699, in Combination with Temozolomide
A. Hilary Calvert, Newcastle General Hospital, Newcastle upon Tyne, England

A Phase II Study of Temsirolimus (CCI-779) in Patients with Metastatic and/or Locally Recurrent Endometrial Cancer – NCIC CTG IND 160
Amit M. Oza, Princess Margaret Hospital, Toronto, ON, Canada

5:30 - 7:30 p.m. Poster Session B (continued)/Exhibits
Hall C

Thursday, November 17

7:00 - 8:00 a.m. Continental Breakfast
Grand Hall

8:00 - 10:00 a.m. Plenary Session 5: Apoptosis Pathway Targeting Agents
Ballroom

Chairpersons: John C. Reed, The Burnham Institute, La Jolla, CA, and E. G. Elisabeth de Vries, University Hospital, Groningen, The Netherlands

Apoptosis-Based Therapies for Cancer*
John C. Reed

Human Recombinant TRAIL/Apo2L and Agonistic Monoclonal Antibodies to TRAIL Death Receptors from the Laboratory to the Clinic*
E. G. Elisabeth de Vries

Developing Chemotherapeutics that Target Mitochondria*
Craig B. Thompson, University of Pennsylvania, Philadelphia, PA

The IAP Proteins and the XAF1 Antagonist as Cancer Targets*
Robert Korneluk, University of Ottawa, Ottawa, ON, Canada

10:00 - 10:30 a.m. Coffee Break
Ballroom Foyer

10:30 a.m. - 12:30 p.m. Plenary Session 6: Tumor Immunotherapy
Ballroom

Chairpersons: Donald J. Buchsbaum, University of Alabama, Birmingham, AL, and Richard H. J. Begent, University College London, London, England

TRAIL Receptor Targeted Therapy*
Donald J. Buchsbaum

Recombinant Antibody-Based Therapeutics*
Richard H. J. Begent

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
Clinical Trial Results in Patients Treated with a Monoclonal Antibody against TRAIL-R1
Anthony W. Tolcher, Institute for Drug Development, San Antonio, TX

Optimizing Therapy Targeting erbB2: Beyond Herceptin
Mark D. Pegram, UCLA School of Medicine, Los Angeles, CA

12:30 - 2:30 p.m. Poster Session C/Exhibits
Hall C

2:30 - 4:30 p.m. Concurrent Sessions

Concurrent Session 5: Novel Views on Nucleic Acid Targeting
Room 201
Chairpersons: Yves G. Pommier, National Cancer Institute, Bethesda, MD, and John A. Hartley, UCL Medical School, London, England
DNA Targeting with PBD and Polyamide-Based Agents*
John A. Hartley
A Novel Oncogenic Silencing Mechanism Amenable to Small Molecule Targeting*
Laurence H. Hurley, Arizona Cancer Center, Tucson, AZ
Interfacial Inhibition of Protein-Nucleic Acid Interactions: One of Nature’s Paradigms for Drug Discovery*
Yves G. Pommier
Analysis and Application of RNAi against Cancer Associated Genes
Natasha Caplen, National Cancer Institute, Bethesda, MD

Concurrent Session 6: Preclinical Models for Evaluating New Cancer Drugs
Room 204
Chairpersons: Patricia LoRusso, Wayne State University, Detroit, MI, and George F. Vande Woude, Van Andel Research Institute, Grand Rapids, MI
Targeting Met-HGF/SF Signaling in Mice and Humans*
George F. Vande Woude
Utility of Genetically-engineered Mouse Models of Cancer*
Tyler Jacks, Massachusetts Institute of Technology, Cambridge, MA

Modeling Tumors of the Nervous System in Mice to Develop New Therapeutics*
Luis F. Parada, UT Southwestern Medical Center, Dallas, TX

Comparative Oncogenomics in Mouse and Human for Drug Discovery
Lynda Chin, Dana-Farber Cancer Institute, Boston, MA

Concurrent Session 7: Regulatory Aspects of Drug Development: Safety, Efficacy, and Beyond
Marriott Hotel Grand Ballroom ABF, 5th Floor
Chairpersons: Alexander M. M. Eggermont, University Hospital Rotterdam, Rotterdam, The Netherlands, and Richard Pazdur, Food & Drug Administration, Rockville, MD
Development and Regulation of New Drugs in Targeted Subgroups*
Jaap Verweij, Erasmus University Medical Center, Rotterdam, The Netherlands
The Revised European Guidelines for Anticancer Drug Development*
Patrick Therasse, EORTC Data Center, Brussels, Belgium
Recent Guidance on Early Drug Development
Jerry M. Collins, Food & Drug Administration, Rockville, MD
Report on Workshops Dedicated to Endpoints in Cancer Clinical Trials
Ramzi N. Dagher, Food & Drug Administration, Rockville, MD

Concurrent Session 8: Structural Biology Approaches to Drug Development
Marriott Hotel Grand Ballroom CDE, 5th Floor
Chairperson: John Kuriyan, University of California, Berkeley, CA
Overview
John Kuriyan
Discovery of Novel Modular Kinase Inhibitors
Robert McDowell, Sunesis Pharmaceuticals, Inc., South San Francisco, CA
The Structural Basis of Form in Function and Regulation*
Michael K. Rosen, UT Southwestern Medical Center, Dallas, TX
Mechanisms of B-RAF Mediated Oncogenesis in Human Cancer*

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
4:30 - 5:30 p.m.  Proffered Paper Session 3  
Ballroom  
The Discovery of AZD1152: A Novel and Highly Potent Aurora Kinase Inhibitor  
Kevin M. Foote, AstraZeneca Pharmaceuticals, Macclesfield, England  
A Phase II Trial of AP23573, A Novel mTOR Inhibitor, in Patients (Pts) with Advanced Soft Tissue or Bone Sarcoma  
Sant P. Chawla, Century City Hospital, Santa Monica, CA  
Pharmacodynamics of Gemcitabine in Glioblastoma Multiforma  
Godefridus J. Peters, VU University Medical Center, Amsterdam, The Netherlands  
FLT PET as a Non-invasive Marker of Response to MEK Inhibition  
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY

5:30 - 7:30 p.m.  Poster Session C (continued)/Exhibits  
Hall C

Friday, November 18

7:00 - 8:00 a.m.  Continental Breakfast  
Grand Hall

8:00 - 10:00 a.m.  Plenary Session 7: Emerging Targets in Anticancer Therapy  
Ballroom  
Overview  
Daniel J. Hicklin  
HSP90 as a Therapeutic Target in Cancer  
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY  
Screening for Inhibitors of Wnt/β-catenin Signal Transduction  
Trevor Dale, Cardiff School of Biosciences, Cardiff, Wales  
Aurora and Polo as Targets for Cancer Therapy*  
David M. Glover, University of Cambridge, Cambridge, England  
Impact of Activated c-Src on Growth of Human Colorectal Cancer Cells and Their Response to Anticancer Drugs: Ramifications for c-Src Inhibitors*  
Caroline Dive

10:00 - 10:30 a.m.  Coffee Break  
Ballroom Foyer

10:30 a.m. - 12:30 p.m.  Plenary Session 8: Radiation Interactions with Other Therapeutics  
Ballroom  
Chairpersons: Marcel Verheij, Netherlands Cancer Institute, Amsterdam, The Netherlands, and C. Norman Coleman, National Cancer Institute, Bethesda, MD  
Molecular Targets for Radiation Modification*  
C. Norman Coleman  
Chemotherapeutic and Molecularly Targeted Radiosensitizers*  
Theodore S. Lawrence, University of Michigan, Ann Arbor, MI  
EGFR/Radiation Interactions*  
Paul M. Harari, University of Wisconsin, Madison, WI  
Apoptosis-Modulating Agents and Radiotherapy*  
Marcel Verheij

12:30 - 12:45 p.m.  Closing Ceremony  
Ballroom  
Robert B. Diasio, Conference Chairperson

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.